체외진단(IVD) 품질관리 시장 : 제품 유형, 기술, 용도, 최종 사용자별 - 세계 시장 예측(2026-2032년)

The In-Vitro Diagnostics Quality Control Market is projected to grow by USD 2.88 billion at a CAGR of 8.67% by 2032.

In-vitro diagnostics quality control is a mission-critical discipline that safeguards the accuracy, precision, reproducibility, and clinical reliability of laboratory testing. As hospitals, reference laboratories, public health networks, and point-of-care settings expand testing volumes, demand is rising for independent quality control materials, calibrators, proficiency testing, external quality assessment, laboratory information system integration, and standardized quality management practices.

The industry is shaped by internationally recognized requirements such as ISO 15189 for medical laboratories, CLIA requirements in the United States, accreditation practices, EU IVDR obligations, and regulator-led post-market surveillance. These frameworks reinforce the role of IVD quality control in reducing diagnostic error, supporting patient safety, maintaining traceability, and strengthening confidence in clinical decision-making across routine and specialized testing.

Transformative Shifts in the IVD Quality Control Landscape

The IVD quality control landscape is shifting from periodic, manual review toward continuous, risk-based, and digitally connected quality assurance. Laboratories are increasingly managing high-throughput immunoassay, clinical chemistry, hematology, microbiology, coagulation, urinalysis, and molecular diagnostics platforms, which require more sophisticated lot-to-lot verification, peer comparison, internal quality control, and instrument performance monitoring.

Regulatory modernization is also changing supplier and laboratory behavior. The EU IVDR has increased evidence requirements for IVD products, while FDA quality system expectations, global accreditation programs, and post-pandemic investments in diagnostic resilience have elevated demand for traceable, commutable, stable, and assay-relevant QC materials across centralized, near-patient, and decentralized testing environments.

Cumulative Impact of Artificial Intelligence on IVD Quality Control

Artificial intelligence is adding cumulative value across IVD quality control by improving anomaly detection, predictive maintenance, workflow triage, and statistical process monitoring. AI-enabled middleware can analyze Levey-Jennings trends, Westgard rule violations, peer group performance, reagent lot shifts, calibration bias, and instrument drift faster than manual review, helping laboratories intervene before quality failures affect patient results.

The strongest near-term impact is where AI supports, rather than replaces, validated quality management systems. Adoption depends on data integrity, explainability, cybersecurity, documented validation, auditability, and alignment with laboratory accreditation requirements. For QC material suppliers and diagnostic platform providers, AI creates opportunities to differentiate through connected controls, remote monitoring, automated exception management, and evidence-based decision support.

Key Regional Insights for IVD Quality Control

Asia-Pacific is expanding as China, India, Japan, South Korea, ASEAN countries, and Australia invest in healthcare infrastructure, infectious disease testing, oncology diagnostics, chronic disease management, and laboratory accreditation. China's NMPA oversight, Japan's PMDA pathway, India's evolving CDSCO framework, South Korea's MFDS regulation, and Australia's NATA-accredited laboratory ecosystem are strengthening the need for reliable IVD quality control across routine and advanced diagnostics.

North America remains a mature, high-compliance region led by the United States and Canada, where CLIA, FDA quality system expectations, accreditation standards, and provincial laboratory requirements support sustained adoption of third-party controls, proficiency testing, and digital QC data management. Europe is being reshaped by IVDR implementation, ISO 15189-based laboratory competence, and stronger performance evidence expectations, while Latin America is led by Brazil and Mexico as laboratories modernize under ANVISA and COFEPRIS influence. The Middle East is advancing through GCC healthcare investment, national screening programs, and hospital accreditation, while Africa's progress is tied to infectious disease programs, WHO-aligned laboratory quality systems, antimicrobial resistance surveillance, and expanded external quality assessment access.

Key Group Insights Across Global IVD Quality Control Markets

ASEAN markets are strengthening diagnostic quality through laboratory modernization, regional regulatory convergence, expanding universal health coverage initiatives, and growing access to molecular and point-of-care testing. The GCC is prioritizing high-quality hospital networks, national screening programs, medical tourism, and medical laboratory accreditation, creating demand for robust QC materials, proficiency testing, and digital quality systems.

The European Union is defined by IVDR implementation, notified body capacity, post-market performance follow-up, and evidence-based performance expectations, making quality control central to regulatory compliance and market access. BRICS countries combine scale with diverse regulatory maturity, creating opportunities for localized QC production, distributor education, and laboratory training. G7 markets lead in automation, accreditation, advanced diagnostics, and cybersecurity-aware data integration, while NATO countries increasingly view diagnostic readiness, supply security, and interoperable laboratory capacity as components of health system resilience.

Key Country Insights for IVD Quality Control

The United States leads through CLIA-regulated laboratories, FDA oversight, accreditation-driven quality systems, and strong use of third-party controls, proficiency testing, and peer comparison programs. Canada emphasizes provincial quality systems and accredited laboratory practice, while Mexico and Brazil are expanding diagnostic access under COFEPRIS and ANVISA oversight. In Europe, the United Kingdom, Germany, France, Italy, and Spain are advancing through ISO-aligned laboratory practices, national accreditation structures, and IVDR-influenced product requirements, while Russia maintains demand across hospital, regional, and public-sector diagnostic networks.

China is scaling domestic IVD manufacturing, hospital laboratory capacity, and NMPA-regulated diagnostic quality expectations; India is expanding diagnostics through public health programs and private laboratory networks; and Japan prioritizes precision, automation, quality assurance, and testing needs linked to an aging population. Australia maintains rigorous accreditation through NATA-linked systems and strong external quality assessment participation, while South Korea continues to grow through advanced diagnostics, export-oriented IVD manufacturing, digital health infrastructure, and technologically mature clinical laboratories.

Actionable Recommendations for IVD Quality Control Leaders

Industry leaders should prioritize commutable, matrix-appropriate, stable, and clinically relevant quality control materials that perform across multi-vendor testing platforms and diverse assay methodologies. Investment in lot-to-lot verification support, stability documentation, traceability, value assignment, uncertainty communication, and regulatory-ready technical files will improve competitiveness as laboratories demand higher confidence in QC performance.

Organizations should also build digital ecosystems around QC data, including peer comparison, middleware integration, automated rule monitoring, audit-ready reporting, and secure cloud-based analytics. Strategic partnerships with accredited laboratories, reference institutions, public health programs, and regional distributors can accelerate adoption, while training programs in ISO 15189, Westgard rules, risk-based quality management, and external quality assessment can strengthen customer retention and operational credibility.

Research Methodology for IVD Quality Control Analysis

This executive summary is based on a structured review of verified industry, regulatory, and clinical laboratory sources, including international laboratory standards, publicly available regulator guidance, accreditation frameworks, and established quality management practices in medical testing. The analysis considers product categories such as independent controls, calibrators, data management tools, proficiency testing, external quality assessment, and quality assurance services.

Regional and country insights were developed by evaluating regulatory maturity, healthcare infrastructure, diagnostic testing demand, laboratory accreditation adoption, public health investment, and adoption of automated and molecular diagnostic technologies. The methodology emphasizes data-backed interpretation, cross-source validation, and practical relevance for manufacturers, laboratories, distributors, healthcare providers, and investors operating in the IVD quality control ecosystem.

Conclusion: Quality Control as the Foundation of Reliable Diagnostics

In-vitro diagnostics quality control is becoming more strategic as laboratories face rising test complexity, stricter regulatory expectations, workforce constraints, and growing pressure to deliver accurate results at scale. The industry's direction will be shaped by independent QC adoption, digital quality management, AI-supported monitoring, traceable materials, and broader use of proficiency testing and external quality assessment.

Organizations that combine scientifically robust QC materials with connected analytics, regulatory readiness, technical education, and regional expertise will be best positioned to grow responsibly. As diagnostic testing expands across centralized laboratories, decentralized care, public health networks, and point-of-care environments, quality control will remain essential to patient safety, clinical confidence, and sustainable IVD development.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. In-Vitro Diagnostics Quality Control Market, by Product Type

• 7.1. Analyzers & Instruments
  • 7.1.1. Automated Systems
  • 7.1.2. Semi-Automated Systems
• 7.2. Control Materials
• 7.3. QC Reagents
  • 7.3.1. Liquid Controls
  • 7.3.2. Lyophilized Controls
• 7.4. Software Solutions
  • 7.4.1. Data Management Systems
  • 7.4.2. LIMS
  • 7.4.3. QC Software

8. In-Vitro Diagnostics Quality Control Market, by Technology

• 8.1. Clinical Chemistry
  • 8.1.1. Colorimetric
  • 8.1.2. Turbidimetric
• 8.2. Hematology
  • 8.2.1. Automated Cell Counters
  • 8.2.2. Flow Cytometry
• 8.3. Immunoassay
  • 8.3.1. Chemiluminescence Immunoassay
  • 8.3.2. ELISA
  • 8.3.3. Fluorescence Immunoassay
• 8.4. Microbiology
  • 8.4.1. Culture
  • 8.4.2. PCR
• 8.5. Molecular Diagnostics
  • 8.5.1. Next-Generation Sequencing
  • 8.5.2. PCR

9. In-Vitro Diagnostics Quality Control Market, by Application

• 9.1. Cardiology
  • 9.1.1. Cardiac Marker Testing
  • 9.1.2. Point-Of-Care Testing
• 9.2. Genetic Testing
  • 9.2.1. Carrier Screening
  • 9.2.2. Prenatal Testing
• 9.3. Infectious Disease Testing
  • 9.3.1. Bacterial Detection
  • 9.3.2. Viral Detection
• 9.4. Oncology
  • 9.4.1. Minimal Residual Disease
  • 9.4.2. Tumor Marker Testing
• 9.5. Toxicology
  • 9.5.1. Drugs Of Abuse
  • 9.5.2. Therapeutic Drug Monitoring

10. In-Vitro Diagnostics Quality Control Market, by End User

• 10.1. Blood Banks
  • 10.1.1. National Blood Banks
  • 10.1.2. Regional Blood Banks
• 10.2. Diagnostic Laboratories
  • 10.2.1. Hospital-Based Laboratories
  • 10.2.2. Independent Laboratories
• 10.3. Hospitals & Clinics
  • 10.3.1. Clinic Laboratories
  • 10.3.2. Reference Laboratories
• 10.4. Research Institutes
  • 10.4.1. Academic Institutes
  • 10.4.2. Private Research Laboratories

11. In-Vitro Diagnostics Quality Control Market, by Region

• 11.1. Asia-Pacific
• 11.2. North America
• 11.3. Latin America
• 11.4. Europe
• 11.5. Middle East
• 11.6. Africa

12. In-Vitro Diagnostics Quality Control Market, by Group

• 12.1. ASEAN
• 12.2. GCC
• 12.3. European Union
• 12.4. BRICS
• 12.5. G7
• 12.6. NATO

13. In-Vitro Diagnostics Quality Control Market, by Country

• 13.1. United States
• 13.2. Canada
• 13.3. Mexico
• 13.4. Brazil
• 13.5. United Kingdom
• 13.6. Germany
• 13.7. France
• 13.8. Russia
• 13.9. Italy
• 13.10. Spain
• 13.11. China
• 13.12. India
• 13.13. Japan
• 13.14. Australia
• 13.15. South Korea

14. Competitive Landscape

• 14.1. Market Concentration Analysis, 2025
  • 14.1.1. Concentration Ratio (CR)
  • 14.1.2. Herfindahl Hirschman Index (HHI)
• 14.2. Recent Developments & Impact Analysis, 2025
• 14.3. Product Portfolio Analysis, 2025
• 14.4. Benchmarking Analysis, 2025

15. Company Profiles

• 15.1. Abbott Laboratories
• 15.2. AccuBioTech Co., Ltd.
• 15.3. Becton, Dickinson and Company
• 15.4. Bio-Rad Laboratories, Inc.
• 15.5. Bio-Techne Corporation
• 15.6. bioMerieux SA
• 15.7. BioSystems S.A.
• 15.8. Danaher Corporation
• 15.9. DiaSorin S.p.A.
• 15.10. EKF Diagnostics Holdings plc
• 15.11. F. Hoffmann-La Roche Ltd.
• 15.12. Fujirebio Holdings, Inc.
• 15.13. Helena Laboratories
• 15.14. Instand e.V.
• 15.15. LGC Limited
• 15.16. Maine Molecular Quality Controls, Inc.
• 15.17. Meridian Bioscience, Inc.
• 15.18. Microbiologics Inc.
• 15.19. Microbix Biosystems Inc.
• 15.20. Qnostics Ltd.
• 15.21. QuidelOrtho Corporation
• 15.22. Randox Laboratories Ltd.
• 15.23. Randox Toxicology
• 15.24. SEKISUI Diagnostics, LLC
• 15.25. SeraCare Life Sciences
• 15.26. Siemens Healthineers AG
• 15.27. Sun Diagnostics, LLC
• 15.28. Sysmex Corporation
• 15.29. Technopath Clinical Diagnostics
• 15.30. Thermo Fisher Scientific Inc.